DPP4 and vulvovaginitis: In an initial analysis, the occurrence of genital candida infections (vaginitis and vulvovaginitis in women; balanitis, balanoposthitis, phimosis, and paraphimosis in men) in those taking SGLT2i vs. DPP4-i was evaluated.